The latest news from academia, regulators
research labs and other things of interest
Posted: March 8, 2010
nanoMR Names Chief Scientific Officer
(Nanowerk News) nanoMR, an emerging diagnostic company that develops real-time, ultrasensitive technology for detecting pathogens in biological samples, today announced the appointment of Colin W. Dykes, Ph.D., as chief scientific officer. His primary responsibility will be to establish studies that validate nanoMR’s pathogen detection system in clinical settings.
“Colin’s years of experience and success working with emerging diagnostic and biotechnology companies make him an enormous asset to our company as we prepare to launch our first diagnostic product, an inexpensive medical device that enables highly sensitive, expedient detection of bacteria in blood,” said Victor Esch, Ph.D., nanoMR president and CEO. “One of his key roles will be to work with opinion leaders in diagnostic microbiology to generate the clinical data required for product launch in 2012.”
Prior to joining nanoMR, Dykes served as CSO and executive vice president at OpGen Inc., a Gaithersburg, Md.-based company that provides molecular diagnostics for clinical and life science applications. During his eight-year tenure, Dykes oversaw the company’s scientific and business development programs and established collaborative studies with leading clinical microbiology labs. He also played a major role in raising more than $25 million in private equity financing.
Previously, Dykes served as vice president of research at Variagenics (now Nuvelo), a pharmacogenomics service business in Cambridge, Mass., where his duties included developing partnerships with pharmaceutical/biotech companies and raising capital, including a successful initial public offering in July 2000. Prior to Variagenics, Dykes spent 16 years in research and development at GlaxoWellcome (now GlaxoSmithKline), where he established the company’s U.K.-based human genetics and genomics programs. Dykes holds a doctorate in biochemistry from University College, Cardiff, Wales, and spent four years conducting post-doctoral research at Vanderbilt University, Nashville, Tenn.
nanoMR is an early stage life sciences company that develops novel diagnostic systems for the rapid, ultrasensitive detection of pathogens in whole blood. nanoMR’s systems couple immunochemistry with patented NMR technology to produce small, simple, inexpensive devices that offer unparalleled speed and sensitivity. The company’s first product addresses the blood culture market, demonstrating detection of blood-borne infections in minutes, compared with days for conventional blood culture systems. nanoMR was founded in 2007 by renowned researchers from the University of New Mexico.